Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524832 | 1.00 | FABP5 (0.44) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4896949 | 0.98 | FABP5 (0.45) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL28659758 | 0.98 | FABP5 (0.45) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL11902423 | 0.94 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL20681006 | 0.94 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4736280 | 0.85 | KMT2A (0.40) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4736278 | 0.85 | KMT2A (0.40) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29913804 | 0.81 | FABP5 (0.47) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL11964044 | 0.81 | KMT2A (0.48) | FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL16095352 | 0.80 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101023079-B | Substituted hydantoins for the treatment of cancer | HOFFMANN LA ROCHE | 2010-05-05 | — | — | CN | disclosed |
| CN-101023079-A | Substituted hydantoins for the treatment of cancer | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | CN | disclosed |
| EP-1531846-A4 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | US GOV HEALTH & HUMAN SERV (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050171014-A1 | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1531846-A2 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003072754-A2 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171014-A1 | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use | VCL, SELPLG, L3MBTL1 | FABP5 805/4885FABP7 546/4885KMT2A 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.